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Background: Drug resistance (DR) is one of the major hur-
dles in HIV treatment. HIV RNA based DR testing is relatively
expensive and infeasible compared to DNA based, in setting where
transport of specimen to regional/central laboratory is needed. Pre-
vious report states concordance between RNA andDNADRpattern.
Patient with suppressed viral load (SVL) may harbor DR, which
cannot be detected by conventional DR assay; hence PBMC DNA
sequencing and Allele speciﬁc PCR (ASPCR) which can quantify
minority variants, can predict adherence status and predisposition
to failing treatment; which can be managed earlier.
Methods & Materials: We examined reverse transcriptase (RT)
sequence in PBMC DNA of patients with SVL for DR using conven-
tional Sanger sequencing and ASPCR for RT mutations K103N and
K65R. DR was based in 2014 IAS-USA DR list.
Results: We analyzed n=90 on TDF regimen (82, 1st line and
8, 2nd line), with median age 38 years, n=50 being female; all had
subtype C infection and showed monophyletic clustering. Any DR
mutations (DRM) were observed in n=12 (13.3%), NRTI DRM in n=8
(8.9%), NNRTI DRM in n=11 (12.2%), and both in n=8 (8.9%). Major
NRTI and NNRTI DRM observed was M184I/V (7.8%), K70R (3.3%)
and V106A/M (4.4%), K103N (3.3%) respectively. Although, popu-
lation genotyping shows K65R and K103N DRM in none and 3.3%,
respectively. ASPCR result shows 32/30 had >1%, 8/13 had > 5% and
3/ 9 had >10% K65R/K103N, respectively. K65R, and K103N nega-
tive by population genotyping and positive (>10%) by ASPCR was
observed in 3.3% and 6.7%, respectively. Mutation pattern shows
none showed resistance to TDF despite being in that regimen, in
contrast resistance for NVP and EFV was observed in 7.8%.
Conclusion: PBMC genotyping among suppressed has shown
resistance mutation among 13%, does the mutations observed
reﬂect recent archival is a big question. In this scenario how reliable
it is tomanage HIV infection among suppressed taking archived DR
into consideration, needs to be substantiated. In the other way on
considering PBMC DNA as recent archival; based on ASPCR result,
the minor proportion of resistant virus corroborates the ongoing
minimal viral replication, which is one of the hurdle in HIV cure.
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Background: High baseline viral load is implicated in rapid dis-
ease progression, as is often the case in resource-limited settings.
Intriguingly, despite higher baseline viral loads, ﬁrst-line antiretro-
viral treatment (ART) of HIV-1C infection in India elicits a response
comparable to that of HIV-1B infection in the west. Models of viral
dynamics, applied to HIV-1B infection, have shed light on viral
decay dynamics and elucidated markers of treatment outcome,
although such studies forHIV-1C are lacking.Wehypothesized that
the HIV-1C strain in India is less virulent than the HIV-1B strain in
the west, leading to a favourable treatment response.
Methods & Materials: To test this hypothesis, we measured
viral decay dynamics during treatment and analyzed the data using
a mathematical model to estimate the within-host basic reproduc-
tive ratio, R0, a quantitative measure of virulence, and the critical
efﬁcacy for successful treatment, ec. Patientswere initiated onﬁrst-
line ART in India and followed for the ﬁrst 6 months of treatment.
Viral load, CD4+ T-cell count, and adherence data were collected
at baseline, 4, 12, 16 and 24 weeks following ART initiation. Drug
resistance genotyping was done at baseline.
Results: Among 257 patients with complete data (mean age
36.2 years and 60% male), mean baseline viral load was 5.7
log10 copies/mL. At 6 months, 87.5% had undetectable viral
load. Sub-optimal adherence (<95%) (p<0.001) and primary drug
resistance mutations (p=0.029) were associated with virological
non-response. Our mathematical model, considering the dynamics
of productively and long-lived infected cells, provided good ﬁts to
the viral load data. We estimated the median R0 to be 5.3 (IQR: 4.5-
7.1),which is signiﬁcantly smaller (p=0.001) than current estimates
for HIV-1B (median R0∼8), indicating lower virulence of HIV-1C
thanHIV-1B. The corresponding ec for HIV-1C is∼0.8, again smaller
than that for HIV-1B.
Conclusion: The lower R0 and ec imply that responses can
be achieved with lower dosages and/or adherence, potentially
explaining the favourable treatment response of HIV-1C infection
in India despite the high baseline viral loads. The lower virulence
of HIV-1C may also underlie its growing global spread.
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